Ligbas, Rosemarie H.

HRN: 14-15-41  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/21/2023
CO-AMOXICLAV 625MG (TAB)
06/21/2023
06/28/2023
PO
625mg
BID
Laceration, Fracture
Waiting Final Action 
06/24/2023
CO-AMOXICLAV 625MG (TAB)
06/24/2023
06/27/2023
PO
625mg
Q8hrs
Fracture
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: